Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC

NCT07639242 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

60

Enrollment

OTHER

Sponsor class

Stopped Administrative

Conditions

Lung Cancer
Lung Cancer (NSCLC)
Locally Advanced NSCLC
Metastatic NSCLC - Non-Small Cell Lung Cancer

Interventions

DRUG: Olomorasib
DRUG: Pembrolizumab

Sponsor

UNC Lineberger Comprehensive Cancer Center